EP 4422697 A1 20240904 - TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOF
Title (en)
TLR AGONIST IMMUNOCONJUGATES WITH CYSTEINE-MUTANT ANTIBODIES, AND USES THEREOF
Title (de)
TLR-AGONIST-IMMUNKONJUGATE MIT CYSTEINMUTANTEN ANTIKÖRPERN UND VERWENDUNGEN DAVON
Title (fr)
IMMUNOCONJUGUÉS AGONISTES DE TLR AVEC DES ANTICORPS MUTANTS DE CYSTÉINE, ET LEURS UTILISATIONS
Publication
Application
Priority
- US 202163273379 P 20211029
- US 2022048224 W 20221028
Abstract (en)
[origin: WO2023076599A1] The invention provides immunoconjugates comprising a cysteine-mutant antibody covalently attached to one or more TLR agonist moieties by a linker. The invention further provides methods of treating cancer with the immunoconjugates.
IPC 8 full level
A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 47/68 (2017.08); A61K 47/6851 (2017.08)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2023076599 A1 20230504; CA 3234604 A1 20230504; CN 118475372 A 20240809; EP 4422697 A1 20240904
DOCDB simple family (application)
US 2022048224 W 20221028; CA 3234604 A 20221028; CN 202280086855 A 20221028; EP 22814567 A 20221028